261 related articles for article (PubMed ID: 32690647)
21. Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis.
Labuda SM; Seaworth B; Dasgupta S; Goswami ND;
Lancet Respir Med; 2024 Feb; 12(2):e5-e6. PubMed ID: 38043563
[No Abstract] [Full Text] [Related]
22. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
Günther G; Guglielmetti L; Kherabi Y; Duarte R; Lange C;
Clin Microbiol Infect; 2024 Mar; ():. PubMed ID: 38490355
[TBL] [Abstract][Full Text] [Related]
23. Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant
Xu J; Converse PJ; Upton AM; Mdluli K; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526488
[TBL] [Abstract][Full Text] [Related]
24. Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid.
Howell P; Upton C; Mvuna N; Olugbosi M
BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34876446
[TBL] [Abstract][Full Text] [Related]
25. Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.
Mulder C; Rupert S; Setiawan E; Mambetova E; Edo P; Sugiharto J; Useni S; Malhotra S; Cook-Scalise S; Pambudi I; Kadyrov A; Lawanson A; van den Hof S; Gebhard A; Juneja S; Sohn H
BMJ Glob Health; 2022 Jan; 7(1):. PubMed ID: 34992077
[TBL] [Abstract][Full Text] [Related]
26. Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.
Tasneen R; Betoudji F; Tyagi S; Li SY; Williams K; Converse PJ; Dartois V; Yang T; Mendel CM; Mdluli KE; Nuermberger EL
Antimicrob Agents Chemother; 2016 Jan; 60(1):270-7. PubMed ID: 26503656
[TBL] [Abstract][Full Text] [Related]
27. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant
Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644
[TBL] [Abstract][Full Text] [Related]
28. A systematic efficacy analysis of tuberculosis treatment with BPaL-containing regimens using a multiscale modeling approach.
Budak M; Via LE; Weiner DM; Barry CE; Nanda P; Michael G; Mdluli K; Kirschner D
CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):673-685. PubMed ID: 38404200
[TBL] [Abstract][Full Text] [Related]
29. BPaL approved for multidrug-resistant tuberculosis.
Burki T
Lancet Infect Dis; 2019 Oct; 19(10):1063-1064. PubMed ID: 31559963
[No Abstract] [Full Text] [Related]
30. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Conradie F; Diacon AH; Ngubane N; Howell P; Everitt D; Crook AM; Mendel CM; Egizi E; Moreira J; Timm J; McHugh TD; Wills GH; Bateson A; Hunt R; Van Niekerk C; Li M; Olugbosi M; Spigelman M;
N Engl J Med; 2020 Mar; 382(10):893-902. PubMed ID: 32130813
[TBL] [Abstract][Full Text] [Related]
31. Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
Tasneen R; Garcia A; Converse PJ; Zimmerman MD; Dartois V; Kurbatova E; Vernon AA; Carr W; Stout JE; Dooley KE; Nuermberger EL
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0239821. PubMed ID: 35315690
[TBL] [Abstract][Full Text] [Related]
32. Pretomanid for tuberculosis: a systematic review.
Gils T; Lynen L; de Jong BC; Van Deun A; Decroo T
Clin Microbiol Infect; 2022 Jan; 28(1):31-42. PubMed ID: 34400340
[TBL] [Abstract][Full Text] [Related]
33. Daily Dosing for Bedaquiline in Patients with Tuberculosis.
Salinger DH; Nedelman JR; Mendel C; Spigelman M; Hermann DJ
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451504
[TBL] [Abstract][Full Text] [Related]
34. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
Berry C; du Cros P; Fielding K; Gajewski S; Kazounis E; McHugh TD; Merle C; Motta I; Moore DAJ; Nyang'wa BT
Trials; 2022 Jun; 23(1):484. PubMed ID: 35698158
[TBL] [Abstract][Full Text] [Related]
35. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?
Chang KC; Yew WW; Cheung SW; Leung CC; Tam CM; Chau CH; Wen PK; Chan RC
Antimicrob Agents Chemother; 2013 Jul; 57(7):3445-9. PubMed ID: 23650165
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
37. Favourable outcomes in RR-TB patients using BPaL and other WHO-recommended second-line anti-TB drugs.
Rikhotso MC; Ledwaba SE; Ngandu JK; Mavumengwana V; Kinnear CJ; Warren R; Potgieter N; Traoré AN
Int J Tuberc Lung Dis; 2023 Aug; 27(8):599-605. PubMed ID: 37491748
[TBL] [Abstract][Full Text] [Related]
38. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.
Wasserman S; Meintjes G; Maartens G
Expert Rev Anti Infect Ther; 2016 Oct; 14(10):901-15. PubMed ID: 27532292
[TBL] [Abstract][Full Text] [Related]
39. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Yang JS; Kim KJ; Choi H; Lee SH
Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
[TBL] [Abstract][Full Text] [Related]
40. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
Kadura S; King N; Nakhoul M; Zhu H; Theron G; Köser CU; Farhat M
J Antimicrob Chemother; 2020 Aug; 75(8):2031-2043. PubMed ID: 32361756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
